News about "Eli Lilly"

Eli Lilly Enters USD 1.12 Billion Gene-Editing Partnership with Seamless Therapeutics

Eli Lilly and Company has entered into a strategic collaboration worth up to USD 1.12 billion with private gene-editing company Seamless Therapeutics to develop next-generation therapies for hearing loss. The agreement strengthens Lilly’s push into genetic medicines and expands its pipeline beyond its core diabetes and obesity treatments.

Eli Lilly | 29/01/2026 | By Darshana |  139

Innovation Led Growth Dominates Indian Pharma Market in 2025

The India’s pharmaceutical market grew 10.6 percent year-on-year in December 2025, driven by chronic therapies, GLP-1 drugs, and strong innovation-led demand.

Eli Lilly | 15/01/2026 | By News Bureau |  258

ABL Bio Secures USD 40 Million Upfront, USD 15 Million Equity Investment From Eli Lilly

ABL Bio, a company focused on bispecific antibody technologies, announced that it will receive a USD 40 million upfront payment under a license, research, and collaboration agreement for its proprietary Grabody platform, along with a USD 15 million equity investment from Eli Lilly and Company.

Eli Lilly | 29/12/2025 | By Darshana |  155

Eli Lilly Expands USA Manufacturing with Alabama Plant

The site will focus on producing synthetic and peptide-based medicines, including Lilly’s first oral GLP-1 weight-loss therapy, Orforglipron, which the company expects to submit for regulatory approval early next year.

Eli Lilly | 11/12/2025 | By Darshana

FDA Approves Expanded Use of Eli Lilly's Jaypirca in Relapsed or Refractory CLL/SLL

Eli Lilly’s Jaypirca (pirtobrutinib) is the only medicine in CLL or SLL that has been prospectively studied in a randomised trial of patients previously treated with a covalent BTK inhibitor.

Eli Lilly | 04/12/2025 | By Dineshwori |  129

Lilly Lowers Zepbound's Single-dose Vials' Cost

Lilly has reduced the price of its Zepbound (tirzepatide) single-dose vials, reinforcing its commitment to improving affordability and expanding access for people living with obesity.

Eli Lilly | 02/12/2025 | By Dineshwori |  119

Insilico Medicine and Eli Lilly Expand Collaboration to Accelerate AI-Driven Drug Discovery

The partnership aims to combine Insilico’s advanced Pharma.AI platforms with Lilly’s deep expertise in disease biology and drug development to jointly discover and advance innovative therapies for unmet medical needs.

Eli Lilly | 11/11/2025 | By Dineshwori |  320

Eli Lilly and SanegeneBio Partner to Develop RNAi Therapies for Metabolic Diseases

SanegeneBio, a clinical-stage biotechnology company developing RNAi therapeutics, has entered into a global research and licensing collaboration with Eli Lilly and Company to advance RNAi candidates for metabolic diseases.

Eli Lilly | 10/11/2025 | By Dineshwori |  281

Eli Lilly Investing USD 3 Billion in New Netherlands Facility to Boost Oral Medicine Manufacturing Capacity

Eli Lilly has announced plans to invest USD 3 billion in a new manufacturing facility in Katwijk, the Netherlands, to expand its global capacity for producing oral medicines and strengthen its supply chain network.

Eli Lilly | 04/11/2025 | By Dineshwori |  153

Eli Lilly to Pour USD 1.2B into Puerto Rico Facility Expansion Amid USA Manufacturing Push

Eli Lilly announced plans to invest more than USD 1.2 billion to expand and modernise its Lilly del Caribe manufacturing site in Carolina, Puerto Rico, as part of its broader initiative to enhance pharmaceutical production in the United States.

Eli Lilly | 03/11/2025 | By Darshana |  188